These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
564 related items for PubMed ID: 16810470
21. Left ventricular hypertrophy: how to influence an important risk factor in hypertension. Agabiti-Rosei E, Muiesan ML. J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098 [Abstract] [Full Text] [Related]
22. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy. Dahlöf B. Blood Press Suppl; 1994 Jan; 2():35-40. PubMed ID: 8061844 [Abstract] [Full Text] [Related]
23. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension]. MMW Fortschr Med; 2006 Jun 29; 148(26):50-1. PubMed ID: 16875381 [No Abstract] [Full Text] [Related]
27. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study). Smebye ML, Iversen EK, Høieggen A, Flaa A, Os I, Kjeldsen SE, Olsen MH, Chattopadhyay A, Hille DA, Lyle PA, Devereux RB, Dahlöf B. Am J Cardiol; 2007 Sep 01; 100(5):855-9. PubMed ID: 17719333 [Abstract] [Full Text] [Related]
32. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan. Avanza AC, El Aouar LM, Mill JG. Arq Bras Cardiol; 2000 Feb 01; 74(2):103-17. PubMed ID: 10904284 [Abstract] [Full Text] [Related]
35. [Hypertension and the heart]. Wachtell K, Andersen NH, Svendsen TL. Ugeskr Laeger; 2009 Jun 15; 171(25):2113-6. PubMed ID: 19671394 [Abstract] [Full Text] [Related]
36. Effect of telmisartan on QT interval variability and autonomic control in hypertensive patients with left ventricular hypertrophy. Galetta F, Franzoni F, Fallahi P, Tocchini L, Graci F, Carpi A, Antonelli A, Santoro G. Biomed Pharmacother; 2010 Oct 15; 64(8):516-20. PubMed ID: 20044234 [Abstract] [Full Text] [Related]
37. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S, ONTARGET/TRANSCEND Investigators. Circulation; 2009 Oct 06; 120(14):1380-9. PubMed ID: 19770395 [Abstract] [Full Text] [Related]
38. Angiotensin II type 1 receptor blockade: high hopes sent back to reality? Grothusen A, Divchev D, Luchtefeld M, Schieffer B. Minerva Cardioangiol; 2009 Dec 06; 57(6):773-85. PubMed ID: 19942847 [Abstract] [Full Text] [Related]
40. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Devereux RB, de Faire U, Fyhrquist F, Harris KE, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Hille DA, Dahlöf B. Curr Med Res Opin; 2007 Feb 06; 23(2):259-70. PubMed ID: 17288679 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]